A federal district court ruled in favor of the Health Resources and Services Administration, but raised questions about ...

By Jennifer Rigby LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

New Delhi: Novartis Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

LONDON, May 12 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health ...